Skip to content

EyePoint, Inc. EYPT EPS (Diluted)

EPS (Diluted) at other companies

Merck & Co. logo
Merck & Co.MRK
-$1.72-186%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$6.75-7.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$0.40-5.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$0.94+13.8%
HRO
HarrowHROW
-$0.74-48.0%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$0.10+63.0%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's EPS (diluted)?
EyePoint, Inc. (EYPT) reported EPS (diluted) of -$0.99 in Q1 2026.
How has EyePoint, Inc. 's EPS (diluted) changed year-over-year?
EyePoint, Inc. 's EPS (diluted) decreased by 52.3% year-over-year, from -$0.65 to -$0.99.
What is the long-term trend for EyePoint, Inc. 's EPS (diluted)?
Over 4 years (2021 to 2025), EyePoint, Inc. 's EPS (diluted) has grown at a 11.6% compound annual growth rate (CAGR), from -$2.04 to -$3.17.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.